Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Breast 1

Conditions

Breast Neoplasms 95Breast Neoplasms, Male 6Advanced Breast Cancer 4Triple Negative Breast Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Infertility 2Sexual Dysfunctions, Psychological 1Primary Ovarian Insufficiency 1Patient Compliance 1Osteitis Deformans 1Inflammatory Breast Neoplasms 1Hyperlipidemias 1Hormone-sensitive Metastatic Breast Cancer 1Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1Hereditary Sensory and Autonomic Neuropathies 1HER2-positive Breast Cancer 1HER2 Negative Breast Cancer 1Breast Diseases 1Breast Cancer Invasive 1Anatomic Stage I Breast Cancer AJCC v8 1Advanced Metastatic Breast Cancer 1

Interventions

exemestane 1Testosterone Propionate 1Phenylephrine 1Leuprolide 1Letrozole 1Goserelin 1Gonadotropin-Releasing Hormone 1Exercise Movement Techniques 1Bupropion 1Aromatase Inhibitors 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sexual Dysfunctions, Psychological × Goserelin × Breast × Clear all
NCT07596212 2026-05-19

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

University of Illinois at Chicago

Phase 1/2 Not yet recruiting
100 enrolled
BreastOther

Breast Neoplasms, Sexual Dysfunctions, Psychological

Data powered by HemOnc (CC BY 4.0) Colophon âš¡